PE20141585A1 - Composicion farmaceutica estabilizada a base de un compuesto no petidico - Google Patents
Composicion farmaceutica estabilizada a base de un compuesto no petidicoInfo
- Publication number
- PE20141585A1 PE20141585A1 PE2014000933A PE2014000933A PE20141585A1 PE 20141585 A1 PE20141585 A1 PE 20141585A1 PE 2014000933 A PE2014000933 A PE 2014000933A PE 2014000933 A PE2014000933 A PE 2014000933A PE 20141585 A1 PE20141585 A1 PE 20141585A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- pyrrol
- pyridin
- composition
- content
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (I) UN INGREDIENTE FARMACEUTICAMENTE ACTIVO NO PEPTIDICO QUE TIENE UN GRUPO AMINO PRIMARIO O SECUNDARIO SELECCIONADO DE 1-[5-(2-FLUOROFENIL)-1-(PIRIDIN-3-ILSUFONIL)-1H-PIRROL-3-IL]-N-METILMETANAMINA; N-METIL-1-[5-(2-METILFENIL)-1-(PIRIDIN-3-ILSULFONIL)-1H-PIRROL-3-IL]METANAMINA; O 1-[4-FLUORO-5-(2-FLUOROPIRIDIN-3-IL)-1-(PIRIDIN-3-ILSULFONIL)-1H-PIRROL-3-IL]-N-METILMETANAMINA O SALES DE LOS MISMOS, CON UN CONTENIDO DE 0,39 - 26,72% EN LA COMPOSICION; (II) UN EXCIPIENTE SELECCIONADO DE MANITOL, CROSCARMELOSA SODICA, HIDROXIPROPILCELULOSA, POLIETILENGLICOL, ENTRE OTROS, CON UN CONTENIDO DE 63,28 - 99,35% EN LA COMPOSICION; Y (III) UN COMPUESTO ACIDICO COMO ESTABILIZADOR TAL COMO ACIDO FUMARICO, CON UN CONTENIDO DE 0,05 - 10% EN LA COMPOSICION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008194219 | 2008-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141585A1 true PE20141585A1 (es) | 2014-11-13 |
Family
ID=41327301
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000089A PE20110591A1 (es) | 2008-07-28 | 2009-07-27 | Composicion farmaceutica estabilizada a base de un compuesto no peptidico |
PE2014000508A PE20140977A1 (es) | 2008-07-28 | 2009-07-27 | Composicion farmaceutica estabilizada a base de un compuesto no peptidico |
PE2014000933A PE20141585A1 (es) | 2008-07-28 | 2009-07-27 | Composicion farmaceutica estabilizada a base de un compuesto no petidico |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000089A PE20110591A1 (es) | 2008-07-28 | 2009-07-27 | Composicion farmaceutica estabilizada a base de un compuesto no peptidico |
PE2014000508A PE20140977A1 (es) | 2008-07-28 | 2009-07-27 | Composicion farmaceutica estabilizada a base de un compuesto no peptidico |
Country Status (29)
Country | Link |
---|---|
US (2) | US9186411B2 (es) |
EP (2) | EP2564833B1 (es) |
JP (2) | JP5295356B2 (es) |
KR (1) | KR20110042334A (es) |
CN (3) | CN104784180A (es) |
AR (1) | AR072842A1 (es) |
AU (1) | AU2009277443A1 (es) |
BR (1) | BRPI0916689A2 (es) |
CA (2) | CA2936400C (es) |
CL (1) | CL2011000170A1 (es) |
CO (1) | CO6290638A2 (es) |
CR (1) | CR20110110A (es) |
DO (2) | DOP2011000033A (es) |
EA (2) | EA201201451A1 (es) |
EC (1) | ECSP11010855A (es) |
ES (2) | ES2669592T3 (es) |
GE (2) | GEP20146122B (es) |
IL (2) | IL210735A0 (es) |
MA (1) | MA32556B1 (es) |
MX (1) | MX2011000757A (es) |
MY (2) | MY169461A (es) |
NZ (2) | NZ591344A (es) |
PE (3) | PE20110591A1 (es) |
SG (1) | SG186685A1 (es) |
TW (2) | TW201010992A (es) |
UA (1) | UA103332C2 (es) |
UY (1) | UY32008A (es) |
WO (1) | WO2010013823A2 (es) |
ZA (1) | ZA201101198B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104254322B (zh) * | 2012-02-15 | 2017-06-13 | 武田药品工业株式会社 | 片剂 |
SG11201408511QA (en) | 2012-06-27 | 2015-01-29 | Takeda Pharmaceutical | Liquid preparations of amines and organic acids stabilized by salts |
RU2589701C1 (ru) | 2012-09-19 | 2016-07-10 | Тайхо Фармасьютикал Ко., Лтд. | Фармацевтическая композиция для перорального введения с улучшенными растворимостью и/или всасываемостью |
US20150080845A1 (en) * | 2013-03-14 | 2015-03-19 | Allergan, Inc. | Polymer system for securing implants in syringe needles |
CN105330647A (zh) * | 2014-08-14 | 2016-02-17 | 江苏柯菲平医药股份有限公司 | 吡咯磺酰类衍生物、其制备方法及其在医药上的应用 |
CN105985278A (zh) * | 2015-01-27 | 2016-10-05 | 江苏柯菲平医药股份有限公司 | 吡咯磺酰类衍生物、其制备方法及其在医药上的应用 |
MA41850A (fr) | 2015-03-31 | 2018-02-06 | Takeda Pharmaceuticals Co | Nouvelles utilisations pharmaceutiques |
CN108135915B (zh) | 2015-07-30 | 2021-06-25 | 武田药品工业株式会社 | 片剂 |
CN105106203B (zh) * | 2015-08-17 | 2019-04-05 | 江苏豪森药业集团有限公司 | 富马酸沃诺拉赞的药物组合物及其制备方法 |
CN105030725B (zh) * | 2015-08-26 | 2019-12-10 | 迪沙药业集团有限公司 | 一种富马酸沃诺拉赞肠溶组合物及其制备方法 |
CN105030720B (zh) * | 2015-08-26 | 2019-12-10 | 迪沙药业集团有限公司 | 一种富马酸沃诺拉赞肠溶片及其制备方法 |
CN107224438B (zh) * | 2016-03-25 | 2021-04-06 | 江苏豪森药业集团有限公司 | 富马酸沃诺拉赞药物组合物 |
JP7013454B2 (ja) * | 2016-10-12 | 2022-02-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
CN106580903B (zh) * | 2016-11-17 | 2019-12-13 | 江苏豪森药业集团有限公司 | 罗红霉素缓释药物组合物 |
CN106860852A (zh) * | 2017-02-17 | 2017-06-20 | 王清华 | 一种用于结合治疗胃病的粘液西药 |
AU2018275631A1 (en) | 2017-05-31 | 2019-10-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof |
WO2019013310A1 (en) * | 2017-07-10 | 2019-01-17 | Takeda Pharmaceutical Company Limited | PREPARATION COMPRISING VONOPRAZAN |
CN108558831B (zh) * | 2018-06-08 | 2021-07-27 | 上海璃道医药科技有限公司 | 取代吡咯-4-烷基胺类化合物及其用途 |
CN109288722B (zh) * | 2018-11-09 | 2021-03-30 | 伯德创研(广州)生物科技有限公司 | 一种变色修正肤色的粉底及其制备方法 |
CN110538153B (zh) * | 2019-09-26 | 2022-04-26 | 扬子江药业集团四川海蓉药业有限公司 | 一种高稳定性、快速释放的固体制剂及其制备方法 |
CN111973565A (zh) * | 2020-07-07 | 2020-11-24 | 南京海纳医药科技股份有限公司 | 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法 |
CN111943932B (zh) * | 2020-08-06 | 2023-07-14 | 四川国康药业有限公司 | 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途 |
CN114853728B (zh) * | 2022-05-07 | 2023-11-07 | 四川制药制剂有限公司 | 一种富马酸伏诺拉生片及其制备方法 |
CN115364065B (zh) * | 2022-08-23 | 2024-03-15 | 宁波高新区美诺华医药创新研究院有限公司 | 富马酸伏诺拉生片 |
CN117462507B (zh) * | 2023-12-28 | 2024-03-15 | 山东齐都药业有限公司 | 富马酸伏诺拉生药物组合物及其制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2844351B2 (ja) | 1989-07-13 | 1999-01-06 | 株式会社科薬 | 安定なポリミキシン系抗生物質水性溶液 |
US5422362A (en) | 1993-07-29 | 1995-06-06 | Quadra Logic Technologies, Inc. | Method to inhibit restenosis |
TW483763B (en) | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
FR2745500B1 (fr) | 1996-03-04 | 1998-04-03 | Synthelabo | Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine |
US5834503A (en) | 1996-06-14 | 1998-11-10 | Qlt Phototherapeutics, Inc. | Methods to treat arterial plaque |
FR2752162B1 (fr) | 1996-08-07 | 1998-11-06 | Jouveinal Lab | Comprime de maleate de trimebutine pellicule |
ATE241341T1 (de) * | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | Stabilisierte pharmazeutische zusammensetzung |
JP4730985B2 (ja) | 1997-09-10 | 2011-07-20 | 武田薬品工業株式会社 | 安定化された医薬製剤 |
GB9800526D0 (en) | 1998-01-12 | 1998-03-11 | Ciba Geigy Ag | Organic compounds |
US5962488A (en) * | 1998-04-08 | 1999-10-05 | Roberts Laboratories, Inc. | Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives |
TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
DE60125026T2 (de) | 2000-03-23 | 2007-06-28 | Takeda Pharmaceutical Co. Ltd. | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung |
CN1638773A (zh) | 2001-07-30 | 2005-07-13 | 三菱制药株式会社 | 以氨基苯磺酸衍生物作为活性成分的药物制剂 |
CN1571664A (zh) | 2001-10-17 | 2005-01-26 | 久光制药株式会社 | 经皮吸收型制剂 |
AU2003217820A1 (en) | 2002-02-28 | 2003-09-16 | The Penn State Research Foundation | Periocular drug delivery for diabetic retinopathy |
EP1485094B2 (de) | 2002-03-07 | 2020-03-25 | Boehringer Ingelheim International GmbH | Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze |
US6818662B2 (en) | 2002-05-28 | 2004-11-16 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
DE10233108A1 (de) | 2002-07-20 | 2004-01-29 | Krewel Meuselbach Gmbh | Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel |
AU2003301121A1 (en) * | 2002-12-18 | 2004-07-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
TW200503783A (en) | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
AR045062A1 (es) | 2003-07-18 | 2005-10-12 | Santarus Inc | Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas |
DE10337697A1 (de) | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
JP2005263788A (ja) | 2004-02-17 | 2005-09-29 | Sankyo Co Ltd | インドリン化合物を含有する安定化された医薬組成物 |
JP5168712B2 (ja) | 2004-04-01 | 2013-03-27 | 味の素株式会社 | ナテグリニド含有製剤 |
JP2006001912A (ja) | 2004-06-21 | 2006-01-05 | Chugai Pharmaceut Co Ltd | タンパク質製剤の安定化方法 |
WO2006036024A1 (ja) | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | プロトンポンプ阻害薬 |
CA2582300A1 (en) | 2004-10-05 | 2006-04-13 | Altana Pharma Ag | Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient |
WO2007023931A1 (ja) | 2005-08-25 | 2007-03-01 | Kyowa Hakko Kogyo Co., Ltd. | 血中アルコール濃度上昇抑制用組成物 |
PL1919865T3 (pl) * | 2005-08-30 | 2011-09-30 | Takeda Pharmaceuticals Co | 1-heterocyklilosulfonylo, 2-aminometylo, 5-(hetero-) arylo podstawione pochodne 1-h-pirolu jako kwasowe inhibitory wydzielania |
US20090104264A1 (en) | 2005-12-28 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Controlled release solid preparation |
CA2662938A1 (en) | 2006-09-15 | 2008-03-20 | Astellas Pharma Inc. | Light-stable solid pharmaceutical composition of ramosetron |
JP5074052B2 (ja) | 2007-02-13 | 2012-11-14 | 有限会社愛和ライト | 遊技機 |
US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
EP3162798B1 (en) | 2007-09-28 | 2021-04-14 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compound |
JP5345140B2 (ja) | 2007-09-28 | 2013-11-20 | 武田薬品工業株式会社 | プロトンポンプ阻害剤としての5員複素環化合物 |
US20110059176A1 (en) | 2007-11-22 | 2011-03-10 | The University Of Tokyo | Material for preventing tissue adhesion and material for preventing joint contracture |
-
2009
- 2009-07-27 BR BRPI0916689A patent/BRPI0916689A2/pt not_active IP Right Cessation
- 2009-07-27 TW TW98125164A patent/TW201010992A/zh unknown
- 2009-07-27 US US13/056,593 patent/US9186411B2/en active Active
- 2009-07-27 WO PCT/JP2009/063708 patent/WO2010013823A2/en active Application Filing
- 2009-07-27 AR ARP090102847 patent/AR072842A1/es unknown
- 2009-07-27 EP EP12194777.4A patent/EP2564833B1/en active Active
- 2009-07-27 UY UY32008A patent/UY32008A/es not_active Application Discontinuation
- 2009-07-27 EA EA201201451A patent/EA201201451A1/ru unknown
- 2009-07-27 GE GEAP200912530A patent/GEP20146122B/en unknown
- 2009-07-27 CN CN201510088695.8A patent/CN104784180A/zh active Pending
- 2009-07-27 CN CN201210251154.9A patent/CN102743330B/zh active Active
- 2009-07-27 SG SG2012095162A patent/SG186685A1/en unknown
- 2009-07-27 KR KR20117004549A patent/KR20110042334A/ko not_active Application Discontinuation
- 2009-07-27 UA UAA201102390A patent/UA103332C2/ru unknown
- 2009-07-27 NZ NZ59134409A patent/NZ591344A/xx not_active IP Right Cessation
- 2009-07-27 AU AU2009277443A patent/AU2009277443A1/en not_active Abandoned
- 2009-07-27 MY MYPI2014000760A patent/MY169461A/en unknown
- 2009-07-27 CA CA2936400A patent/CA2936400C/en active Active
- 2009-07-27 EP EP09788013.2A patent/EP2309985B1/en active Active
- 2009-07-27 MY MYPI2011000398A patent/MY156305A/en unknown
- 2009-07-27 CA CA2732243A patent/CA2732243C/en active Active
- 2009-07-27 ES ES09788013.2T patent/ES2669592T3/es active Active
- 2009-07-27 EA EA201170272A patent/EA201170272A1/ru unknown
- 2009-07-27 PE PE2011000089A patent/PE20110591A1/es not_active Application Discontinuation
- 2009-07-27 PE PE2014000508A patent/PE20140977A1/es not_active Application Discontinuation
- 2009-07-27 MX MX2011000757A patent/MX2011000757A/es not_active Application Discontinuation
- 2009-07-27 TW TW103115778A patent/TW201431552A/zh unknown
- 2009-07-27 ES ES12194777.4T patent/ES2660962T3/es active Active
- 2009-07-27 JP JP2011504079A patent/JP5295356B2/ja active Active
- 2009-07-27 CN CN2009801376029A patent/CN102164581A/zh active Pending
- 2009-07-27 PE PE2014000933A patent/PE20141585A1/es not_active Application Discontinuation
- 2009-07-27 NZ NZ60259209A patent/NZ602592A/en not_active IP Right Cessation
- 2009-07-27 GE GEAP200912120A patent/GEP20146166B/en unknown
-
2011
- 2011-01-18 IL IL210735A patent/IL210735A0/en unknown
- 2011-01-27 CL CL2011000170A patent/CL2011000170A1/es unknown
- 2011-01-28 DO DO2011000033A patent/DOP2011000033A/es unknown
- 2011-02-11 MA MA33607A patent/MA32556B1/fr unknown
- 2011-02-15 ZA ZA2011/01198A patent/ZA201101198B/en unknown
- 2011-02-25 CO CO11023140A patent/CO6290638A2/es unknown
- 2011-02-28 EC ECSP11010855 patent/ECSP11010855A/es unknown
- 2011-02-28 CR CR20110110A patent/CR20110110A/es not_active Application Discontinuation
-
2012
- 2012-10-03 JP JP2012221657A patent/JP5593363B2/ja active Active
-
2013
- 2013-05-29 US US13/905,090 patent/US20130261156A1/en active Pending
- 2013-07-31 DO DO2013000172A patent/DOP2013000172A/es unknown
- 2013-10-10 IL IL228817A patent/IL228817A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141585A1 (es) | Composicion farmaceutica estabilizada a base de un compuesto no petidico | |
ES2508290T3 (es) | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo | |
PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
UY32816A (es) | Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa | |
BRPI0923728A2 (pt) | "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase". | |
CR10027A (es) | Nuevos derivados de pirrol fusionado | |
UY30438A1 (es) | Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos | |
EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
CR20120058A (es) | Composiciones nuevas de 1 - [2 - (2,4-dimetil-fenilsulfanil)-fenil] piperazina | |
CO6710904A2 (es) | Formulación farmaceútica para inhibir la hipermeabilidad vascular en un ánimal | |
EA201071218A1 (ru) | Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью | |
RS53056B (en) | PHARMACEUTICAL PREPARATION CONTAINING (1S) -1,5-ANHYDRO-1- [5- (4-ETHOXYBENZYL) -2-METHOXY-4-METHYLPHENYL] -1-THI-D-GLUCITOL AND METFORMIN AND ITS USE IN THE TREATMENT OF DIABETES | |
GEP20135859B (en) | Stable combined pharmaceutical composition | |
PE20110706A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
TW200744583A (en) | Statin stabilizing dosage formulations | |
EA201100104A1 (ru) | Фармацевтическая композиция, содержащая статин | |
TR201803451T4 (tr) | Olmesartan formülasyonlari. | |
PE20070323A1 (es) | Composicion que comprende 4-(2,4-dicloro-5-metoxi-fenilamino)-6-metoxi-7-[3-(4-metil-piperazin-1-il)-propoxi]-quinolin-3-carbonitrilo como inhibidor de tirosina quinasa | |
WO2010018593A3 (en) | Gastric acid resistant benzimidazole multiple unit tablet composition | |
BRPI0416027A (pt) | sistema de entrega de drogas para inibidores de bomba de prótons e processo resultante | |
TR200802061A2 (tr) | Yüksek oranda aktif madde içeren farmasötlk formülasyon. | |
WO2011154830A3 (es) | Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa | |
UA107092C2 (uk) | Заміщені похідні карбамоїлметиламінооцтової кислоти як інгібітори nep | |
AR060660A1 (es) | Derivado de 4-amino-2,6-dimetilfenol, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y usos en estados febriles o asociados al dolor. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |